MX373330B - Composiciones y métodos que comprenden bupropion o compuestos relacionados y dextrometorfano. - Google Patents

Composiciones y métodos que comprenden bupropion o compuestos relacionados y dextrometorfano.

Info

Publication number
MX373330B
MX373330B MX2016005867A MX2016005867A MX373330B MX 373330 B MX373330 B MX 373330B MX 2016005867 A MX2016005867 A MX 2016005867A MX 2016005867 A MX2016005867 A MX 2016005867A MX 373330 B MX373330 B MX 373330B
Authority
MX
Mexico
Prior art keywords
dextromethorphan
compositions
bupropion
methods
related compounds
Prior art date
Application number
MX2016005867A
Other languages
English (en)
Other versions
MX2016005867A (es
Inventor
Herriot Tabuteau
Original Assignee
Antecip Bioventures Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antecip Bioventures Ii Llc filed Critical Antecip Bioventures Ii Llc
Publication of MX2016005867A publication Critical patent/MX2016005867A/es
Publication of MX373330B publication Critical patent/MX373330B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En esta divulgación se describe un método para tratar un trastorno neurológico mediante la administración de un compuesto antidepresivo y dextrometorfano a un ser humano que lo necesita. Este método puede ser útil para seres humanos, los cuales son metabolizadores extensos de dextrometorfano. También se describen composiciones, medicamentos y formas de dosificación que comprenden compuestos antidepresivos y dextrometorfano.
MX2016005867A 2013-11-05 2014-11-05 Composiciones y métodos que comprenden bupropion o compuestos relacionados y dextrometorfano. MX373330B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900354P 2013-11-05 2013-11-05
PCT/US2014/064184 WO2015069809A1 (en) 2013-11-05 2014-11-05 Compositions and methods comprising bupropion or related compounds and dextromethorphan

Publications (2)

Publication Number Publication Date
MX2016005867A MX2016005867A (es) 2016-07-15
MX373330B true MX373330B (es) 2020-05-04

Family

ID=53042051

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020004075A MX388666B (es) 2013-11-05 2014-11-05 Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano
MX2016005867A MX373330B (es) 2013-11-05 2014-11-05 Composiciones y métodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
MX2021015234A MX2021015234A (es) 2013-11-05 2016-05-04 Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020004075A MX388666B (es) 2013-11-05 2014-11-05 Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015234A MX2021015234A (es) 2013-11-05 2016-05-04 Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.

Country Status (12)

Country Link
EP (3) EP3981404A1 (es)
JP (5) JP6605485B2 (es)
KR (4) KR102603013B1 (es)
CN (7) CN113750099A (es)
AU (7) AU2014346807B2 (es)
CA (4) CA3175703C (es)
IL (3) IL298972A (es)
MX (3) MX388666B (es)
MY (1) MY179696A (es)
NZ (1) NZ758428A (es)
SG (4) SG10201911808QA (es)
WO (1) WO2015069809A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12194006B2 (en) 2013-11-05 2025-01-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US12109178B2 (en) 2013-11-05 2024-10-08 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
KR102603013B1 (ko) * 2013-11-05 2023-11-15 안테씨프 바이오벤쳐스 투 엘엘씨 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
EP4166141A1 (en) * 2014-09-14 2023-04-19 Avanir Pharmaceuticals, Inc. Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation and aggression in alzheimer's dementia
KR101931896B1 (ko) * 2014-11-21 2018-12-21 안테씨프 바이오벤쳐스 투 엘엘씨 에리트로히드록시부프로피온을 이용한 약물의 혈장 농도의 조절 방법
WO2017165845A1 (en) * 2016-03-24 2017-09-28 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US12569479B2 (en) 2016-05-25 2026-03-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
TWI795446B (zh) * 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
US20230225995A1 (en) * 2019-01-07 2023-07-20 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
SG11202106392RA (en) * 2019-01-07 2021-07-29 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
CN115697314A (zh) * 2020-03-30 2023-02-03 安泰赛普生物风投二代有限责任公司 安非他酮和右美沙芬组合用于治疗神经病症的用途
US12433884B2 (en) 2020-06-05 2025-10-07 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US12472156B2 (en) 2020-06-05 2025-11-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
WO2022017300A1 (zh) * 2020-07-20 2022-01-27 深圳信立泰药业股份有限公司 一种药物组合物及其应用
KR20230113787A (ko) 2020-12-01 2023-08-01 안테씨프 바이오벤쳐스 투 엘엘씨 우울증 환자의 자살 위험 감소를 위한 부프로피온 및덱스트로메토르판
JP2024503114A (ja) * 2021-01-18 2024-01-24 アンテシップ バイオベンチャーズ トゥー エルエルシー 神経精神疾患に対する抗うつ剤とデキストロメトルファンとの組み合わせ
CN112999350A (zh) * 2021-02-23 2021-06-22 北京斯利安药业有限公司 一种药物组合物、复方制剂及其制备方法与应用
CN119212709A (zh) * 2022-05-17 2024-12-27 安泰赛普生物风投二代有限责任公司 抑郁的治疗
CN118785900A (zh) * 2022-06-30 2024-10-15 艾克萨姆治疗公司 包含安非他酮和半胱氨酸的药物组合物
US12156914B2 (en) 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US12194036B2 (en) 2022-07-07 2025-01-14 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
JP2001527554A (ja) * 1997-05-07 2001-12-25 アルゴス ファーマシューティカル コーポレーション 抗うつ薬とｎｍｄａレセプター拮抗薬とを組み合わせる神経障害痛の治療用組成物及び治療方法
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
JP2009525343A (ja) * 2006-02-03 2009-07-09 アバニール・ファーマシューティカルズ 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物
WO2009006194A1 (en) * 2007-06-28 2009-01-08 Avanir Pharmaceuticals Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
WO2012118562A1 (en) 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US20130274282A1 (en) * 2012-04-16 2013-10-17 Herriot Tabuteau Compositions and methods comprising celecoxib or related compounds and dextromethorphan
KR102603013B1 (ko) * 2013-11-05 2023-11-15 안테씨프 바이오벤쳐스 투 엘엘씨 부프로피온 또는 관련 화합물과 덱스트로메토르판을 포함하는 조성물 및 방법

Also Published As

Publication number Publication date
KR102603013B1 (ko) 2023-11-15
IL283760B1 (en) 2023-01-01
EP3065742A1 (en) 2016-09-14
CN110279682A (zh) 2019-09-27
CA2929415C (en) 2023-01-03
CN113750098A (zh) 2021-12-07
JP2020023543A (ja) 2020-02-13
AU2021202497B2 (en) 2023-03-02
MY179696A (en) 2020-11-11
IL283760B2 (en) 2023-05-01
CN113797205A (zh) 2021-12-17
MX2021015234A (es) 2022-05-26
CN110327338A (zh) 2019-10-15
EP3065742A4 (en) 2017-04-05
JP2021169527A (ja) 2021-10-28
EP3981403A1 (en) 2022-04-13
KR20160070158A (ko) 2016-06-17
MX2020004075A (es) 2021-12-10
MX388666B (es) 2025-03-20
AU2021202497A1 (en) 2021-05-27
IL245504A0 (en) 2016-06-30
JP2016535786A (ja) 2016-11-17
IL298972A (en) 2023-02-01
NZ758432A (en) 2021-07-30
AU2019236614B2 (en) 2021-07-15
NZ719892A (en) 2021-07-30
CN110251517A (zh) 2019-09-20
JP6927601B2 (ja) 2021-09-01
AU2025230795A1 (en) 2025-10-02
SG10201911816XA (en) 2020-01-30
KR20230148385A (ko) 2023-10-24
IL283760A (en) 2021-07-29
CN106163522A (zh) 2016-11-23
CA3256217A1 (en) 2025-10-30
SG10201810888XA (en) 2019-01-30
CN113750099A (zh) 2021-12-07
AU2014346807A1 (en) 2016-05-19
CA3154845A1 (en) 2015-05-14
AU2019275593A1 (en) 2020-01-02
IL245504B (en) 2021-06-30
KR20210068157A (ko) 2021-06-08
CA2929415A1 (en) 2015-05-14
AU2019236614A1 (en) 2019-10-17
KR20220054909A (ko) 2022-05-03
NZ758428A (en) 2021-07-30
AU2018203638C1 (en) 2019-10-24
EP3981404A1 (en) 2022-04-13
AU2023203438A1 (en) 2023-07-06
KR102264179B1 (ko) 2021-06-11
JP2023129646A (ja) 2023-09-14
CA3154845C (en) 2023-02-28
AU2018203638A1 (en) 2018-06-14
AU2019275593B2 (en) 2021-01-28
SG10201911808QA (en) 2020-01-30
NZ758431A (en) 2021-07-30
JP2025175199A (ja) 2025-11-28
AU2019236614C1 (en) 2021-10-14
CA3175703C (en) 2025-08-05
WO2015069809A1 (en) 2015-05-14
SG11201603391XA (en) 2016-05-30
AU2018203638B2 (en) 2019-07-18
AU2014346807B2 (en) 2018-03-22
MX2016005867A (es) 2016-07-15
NZ758425A (en) 2021-07-30
JP6605485B2 (ja) 2019-11-13
AU2023203438B2 (en) 2025-06-26
CA3175703A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
MX2021015234A (es) Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano.
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
MX2018003594A (es) Anticuerpo anti-garp.
NI201600071A (es) Compuestos de inhibidor de autotaxina
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX375254B (es) Una composición antimicrobiana farmacéutica o veterinaria intramamaria que comprende un poliéter ionóforo, o un uso de la misma para tratar mastitis.
BR112015029462A8 (pt) Inibidores de quinase
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
BR112016013946A8 (pt) quinazolin-thf-aminas como inibidores de pde1, composição farmacêutica que os compreende, processo para preparação da referida composição farmacêutica, bem como uso dos composto e kit
MX2015003564A (es) Composiciones y metodos de uso de un compuesto de control de inapetencia.
EA201491581A1 (ru) Везикулярные композиции
UA113859C2 (xx) Похідні спіротієнопіранпіперидину як антагоністи рецептора orl-1 для їх застосування при лікуванні алкогольної залежності та зловживання алкоголем
EA201690445A1 (ru) Лечение рака
EA201690446A1 (ru) Лечение множественной миеломы
BR112016014099A2 (pt) método de tratamento de feridas
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
EA201501177A1 (ru) Фармацевтические композиции

Legal Events

Date Code Title Description
FG Grant or registration